更新于：2024-12-11
Gadoterate Meglumine
钆特酸葡胺
更新于：2024-12-11
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2000-09-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H42GdN5O13 |
InChIKeyRYHQMKVRYNEBNJ-BMWGJIJESA-K |
CAS号92943-93-6 |
关联
43
项与 钆特酸葡胺 相关的临床试验Active surveillance in India of the safety of Dotarem®, a gadolinium-based contrast agent. Post-marketing observational, surveillance study - NA
Advanced Imaging for Pulmonary Fibrosis
Development of Activity MRI (aMRI): Direct Comparison to PET in Human Subjects
100 项与 钆特酸葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆特酸葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆特酸葡胺 相关的专利（医药）
登录后查看更多信息
849
项与 钆特酸葡胺 相关的文献（医药）2024-11-13NANO LETTERS
One-Pot Fabrication of Kinetically Inert Ultrasmall Manganese(II) Chelate-Backboned Polymer Contrast Agents for High-Performance Magnetic Resonance Imaging
Article
作者: Ni, Guohua ; Fu, Shengxiang ; Liu, Li ; Younis, Muhammad Rizwan ; Ai, Hua ; Gu, Haojie ; Wu, Min ; Lui, Su ; Cai, Zhongyuan ; Song, Bin
Traditional macromolecules or nanoscale Mn2+ chelate-based magnetic resonance imaging (MRI) contrast agents (CAs) suffer from complicated and laborious synthesis processes, relatively low kinetic stability and T1 relaxivity, limiting their clinical applications. Herein, we fabricated a series of kinetically inert Mn2+ chelate-backboned polymers, P(MnL-PEG), through a facile and one-pot polymerization process. Particularly, P(MnL-PEG)-3 demonstrates a significantly higher T1 relaxivity of 23.9 Mn mM-1 s-1 at 1.5 T than that of previously reported small molecules and macromolecules or nanoscale Mn2+ chelate-based CAs. Due to its high T1 relaxivity, extended blood circulation, hepatocyte-specific uptake, and kidneys metabolism, P(MnL-PEG)-3 presents significantly enhanced contrast in blood vessel, liver, and kidneys imaging compared to clinical Gd3+-based CAs (Gd-EOB-DTPA and Gd-DOTA) at a dosage of 0.05 mmol Mn/Gd kg-1 BW, and can accurately diagnose orthotopic H22 liver tumors in vivo in animal models. We anticipate that this work will promote the development of clinically relevant MRI CAs.
2024-10-22ENVIRONMENTAL SCIENCE & TECHNOLOGY
Formation of Nitrosamines from the Heterogeneous Reaction of Nitrous Acid and Organic Amines in Indoor Environments
Article
作者: Long, Shiqian ; Yang, Xin ; Yuan, Wenting ; Zhao, Wangchao ; Zheng, Guomao ; Zhu, Lei ; Xu, Jiwen ; Zhou, Li ; Zhang, Lifang ; Ye, Jianhuai ; Liu, Chenglin ; Jiao, Xiaoqiao ; Shen, Huizhong ; Yang, Bo ; Wang, Chen ; Huang, Weilin ; Fu, Tzung-May
Carcinogenic nitrosamines have been widely studied due to their risk to human health. However, the universality and evolutionary processes of their generation, particularly concerning their secondary sources, remain unclear at present. We demonstrated through laboratory flow tube experiments that corresponding nitrosamines were generated from heterogeneous reactions of nitrous acid (HONO) with five structurally diverse amines commonly found indoors, including diphenylamine (DPhA), dibenzylamine (DBzA), dioctylamine (DOtA), N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD), and N-phenyl-1-naphthylamine (PANA). The heterogeneous reaction rate constants of DBzA and DOtA with HONO (∼70 ppb) were 1.21 × 10-3 and 2.13 × 10-3 min-1 at 30% relative humidity (RH), resulting in a lifetime of 13.8 and 7.8 h. As compared to higher RH (∼80%), more nitrosamines were produced from the reaction of HONO with surface-sorbed DBzA, DOtA, 6PPD, and PANA at lower RH (30%), with product yields ranging from <0.1% to 0.5%. Furthermore, we observed the formation of nitroso-6PPDs and nitro-6PPDs during room air exposure of 6PPD in a genuine indoor environment, in addition to various other transformation products indicative of reactions of 6PPD with HONO, NOx, and ozone indoors. This study confirmed the universality of the heterogeneous reaction of surface-sorbed amine with HONO as a source of nitrosamines indoors.
2024-09-26Journal of Physical Chemistry Letters
In Search of Covalency Measure of Gd(III)-Ligand Interactions
Article
作者: Starynowicz, Przemysław ; Siczek, Miłosz ; Janicki, Rafał
Experimental electron density distribution of the [C(NH2)3]3[Gd(EDTA)F2]·H2O crystal was determined. The derived experimental and theoretical (DFT) topological parameters such as ∇2ρc, ρc, bond degree (BD), kinetics, and potential energy were used to study the nature of Gd-O, Gd-F, and Gd-N interactions. The natural charge of the Gd is 1.86; the natural configuration of the cation is [Xe]6s0.134f7.105d0.83, and the covalency of the Gd-L bond is mainly connected with the transfer of charge from the spx ligand orbitals onto the 5d orbitals of the Gd cation. Simultaneously, the donation of charge onto the 6s and 4f orbitals occurs to a lesser extent. Moreover it was found that the donation of the ligand charges onto the Gd(III) is larger for compounds with a lower coordination number. The obtained topological parameters were analyzed in the context of the Gd(III) f-f transition properties, i.e., energy of the excited 2S+1LJ states, Judd-Ofelt intensity parameters, and luminescence lifetimes, of 18 Gd(III) compounds with various O, N, and F donor ligands (DOTA, EDTA, CDTA, DTPA, NTA, EGTA, ODA, F-, H2O, and CO32-). The calculated nephelauxetic β parameter may reflect the penetration degree of electron lone pairs of ligands inside the metal basin. Finally, it was found for the first time that the sum of the Gd(III)-L bond energy (∑EGdL) is correlated with the position of the gravity center of the 8S7/2 → 2S+1LJ transitions and increase of covalency of the Gd(III)-L bonds is associated with decrease of their bond energy. The obtained results may shed light on chemical bonding in systems containing f-elements. Such subtle differences in the covalent contribution to the Ln-L or An-L bond may tune the selectivity of the partitioning processes of lanthanides and actinides.
100 项与 钆特酸葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管疾病 | 美国 | 2013-03-20 | |
| 造影剂 | 日本 | 2000-09-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中枢神经系统疾病 | 临床3期 | 阿根廷 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 奥地利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 巴西 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 智利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 法国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 德国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 意大利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 韩国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 西班牙 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 英国 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Dotarem (Gadobutrol) | 廠築願繭鬱衊齋壓構壓(顧夢襯網艱餘鹽憲製願) = Renal tissue was characterized by tubular damage, pathologic lipid vacuolization, and diffuse mitochondrial toxicity 範蓋繭願鏇顧窪鏇廠顧 (醖繭糧廠襯衊糧膚簾壓 ) 更多 | 不佳 | 2020-10-19 | ||
临床4期 | 37 | 獵鑰簾觸網齋鹹憲願獵(鹹齋醖繭糧觸醖鬱鑰衊) = 壓憲廠衊鹽蓋鬱網選構 簾艱獵淵選窪願壓獵選 (憲蓋壓衊淵糧窪製襯顧, 餘醖鹹憲選獵夢鬱衊構 ~ 網構壓網網鏇構糧窪壓) 更多 | - | 2019-08-08 | |||
临床4期 | - | 51 | 蓋鑰構顧繭淵壓廠壓糧(鑰壓鬱築網範範製積選) = 壓構淵簾積糧齋鏇遞齋 壓齋構膚鹽遞繭遞網壓 (餘襯製蓋簾壓遞夢簾鑰, 艱憲顧糧繭醖築襯糧鬱 ~ 願鹽鏇膚膚觸繭膚鏇淵) 更多 | - | 2017-03-09 | ||
临床4期 | 179 | (MultiHance 0.1 mmol/kg Arm (Reader 1)) | 艱構網願鏇淵齋遞鹽鹹(膚餘簾憲繭夢網積選鹹) = 製糧壓蓋夢醖膚淵膚襯 觸糧鹹構鑰廠糧顧築鏇 (鑰廠夢壓積網鬱襯艱襯, 淵遞廠鹽廠蓋願廠選夢 ~ 窪積鬱鬱鏇鏇壓艱簾製) 更多 | - | 2017-01-10 | ||
(MultiHance 0.1 mmol/kg Arm (Reader 2)) | 艱構網願鏇淵齋遞鹽鹹(膚餘簾憲繭夢網積選鹹) = 簾窪網構築鬱壓鬱鑰遞 觸糧鹹構鑰廠糧顧築鏇 (鑰廠夢壓積網鬱襯艱襯, 製齋衊夢簾獵簾築淵築 ~ 廠鹽顧憲壓壓壓蓋願築) 更多 | ||||||
临床3期 | 416 | (Dotarem (Gadoterate Meglumine )) | 鏇築憲壓鹽鏇鑰膚觸衊(鏇範醖蓋艱願鹹醖築觸) = 廠壓獵鹹廠餘齋餘遞窪 夢夢構艱窪齋觸齋膚壓 (顧築淵齋壓顧築遞簾醖, 淵築觸構願範夢窪築觸 ~ 襯鏇憲齋醖選遞壓積鬱) 更多 | - | 2014-05-29 | ||
(Magnevist (Gadopentetate Dimeglumine)) | 鏇築憲壓鹽鏇鑰膚觸衊(鏇範醖蓋艱願鹹醖築觸) = 夢襯壓糧築製艱鏇鬱獵 夢夢構艱窪齋觸齋膚壓 (顧築淵齋壓顧築遞簾醖, 築醖鬱醖壓製齋鬱夢顧 ~ 鑰夢餘願範憲鹽鹽齋鹹) 更多 | ||||||
临床1期 | - | 10 | 鑰構衊構襯襯範壓鏇製(選窪網鹽鏇獵衊築蓋憲) = No Aes related to gadoterate were reported. No Aes occurred at the injection site during the observation period. There were no clinically relevant changes in mean laboratory values and vital signs. No cases of Nephrogenic Systemic Fibrosis have been reported so far. 觸觸範願醖遞獵醖艱鹽 (製網獵築構襯艱鏇淵鬱 ) | 积极 | 2013-11-05 | ||
临床4期 | 189 | Gadovist (Gadovist) | 憲顧繭獵網簾壓觸膚觸(鏇夢襯夢鹹糧鏇鏇窪鹽) = 艱蓋顧醖築鬱選積鹽構 夢襯蓋鏇艱鏇製繭築壓 (構廠鑰餘醖鹹蓋觸繭選, 齋鹽蓋蓋積獵膚膚膚淵 ~ 鹹醖鑰餘範積簾構願築) 更多 | - | 2012-12-11 | ||
(Dotarem, Interventional) | 憲顧繭獵網簾壓觸膚觸(鏇夢襯夢鹹糧鏇鏇窪鹽) = 製膚簾構糧鏇壓鬱蓋鏇 夢襯蓋鏇艱鏇製繭築壓 (構廠鑰餘醖鹹蓋觸繭選, 齋淵獵壓廠簾願遞鹹願 ~ 範鏇遞廠醖築膚鹽夢壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用